SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.61 HKD | -1.61% |
|
-1.61% | -6.15% |
| 05-02 | Sihuan Pharmaceutical Unit's Lung Cancer Drug NDA Accepted by NMPA, Stocks Shoot Over 10% | MT |
| 04-25 | Sihuan Pharma Unit Wins Bid to Supply Insulin Products to Chinese Government | MT |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company is one of the best yield companies with high dividend expectations.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- With an expected P/E ratio at 61 and 15.25 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -6.15% | 738M | B- | ||
| +32.02% | 694B | C+ | ||
| +29.39% | 593B | B | ||
| -1.78% | 371B | C+ | ||
| +19.92% | 331B | B- | ||
| +6.68% | 290B | C+ | ||
| +14.25% | 239B | B+ | ||
| -3.03% | 209B | A+ | ||
| +10.02% | 209B | B- | ||
| +7.80% | 169B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 460 Stock
- Ratings Sihuan Pharmaceutical Holdings Group Ltd.
